Wow very excited about this one. Hats off Haidut for persevering and getting this done. Any specific studies for Allopregnanolone and Parkinson's disease?
Not directly related to Parkinson's disease, but I have read a full study on the effect of allopregnanolone (APα) on a model of Alzheimer's disease (AD) in mice:
Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice
and in the full article there was:
In addition to cognitive impairment, 35–40% of AD patients can slowly develop extra-pyramidal motor signs or Parkinson’s disease (PD)-like syndromes which increase in prevalence with the developing of AD (Morris et al., 1989; Lopez et al., 1997).
For example, the mice expressing familial AD-linked mutant human amyloid precursor proteins (APPs) exhibit degeneration in the midbrain dopaminergic neurons and PD like motor deficits (Masliah et al., 2001).
As a neurogenic agent with a low molecular weight and easily penetrating blood–brain barrier, APα may potentially treat or prevent parkinsonian symptoms in AD patients.
Compared with the serum and cerebral spinal fluid of age-matched healthy subjects, APα level is much lower in the PD patients (di Michele et al., 2003; Marx et al., 2006; Luchetti et al., 2010; Naylor et al., 2010), which is consistent with evidence that the expression of genes involved in encoding enzymes for APα synthesis is decreased in the post-mortem brain samples of PD subjects (Marx et al., 2006; Naylor et al., 2010).
Last edited: